Assessment of proliferation markers in metastatic melanoma in sentinel lymph nodes
- PMID: 21896579
- DOI: 10.1136/jclinpath-2011-200242
Assessment of proliferation markers in metastatic melanoma in sentinel lymph nodes
Abstract
Aim: Some views on sentinel nodes for melanoma seem to cast doubt on the relevance of micrometastases in the sentinel nodes of patients with melanoma, suggesting that small metastases or isolated tumour cells can be ignored. Tumour dormancy has been proposed for their postulated lack of progression. The implication of the argument seems to be that minute metastases are inactive and therefore non-threatening, whereas larger ones are proliferative and therefore have aggressive potential.
Methods: 54 sentinel lymph nodes were studied with histologically identified micrometastatic melanoma using the protocol accepted by the European Organisation for Research and Treatment of Cancer melanoma group. These were studied with respect to metastasis size and by use of immunohistochemical markers of proliferation (MIB-1) and dormancy (p16).
Results: The authors have demonstrated no correlation between the size of metastases and their proliferative activity. Very small metastases may not show proliferative activity, but this may be a reflection of the small number of assessable cells rather than a genuine reflection of the tumoural characteristics. Furthermore, the minute size of some of these metastases resulted in no residual tumour being present in adjacent sections. Where further sections did show more tumour, these small metastases were invariably p16 negative, suggesting dormancy was not the explanation for the lack of measurable proliferation. Occasionally, larger metastases, clearly not clinically insignificant, showed no proliferative activity presumably, considering their size, a transient phenomenon.
Conclusion: These findings suggest that variable phases in proliferation occur in metastases, and no conclusion of clinical insignificance can be made on the basis of small size.
Similar articles
-
[Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].Ned Tijdschr Geneeskd. 2004 May 1;148(18):884-8. Ned Tijdschr Geneeskd. 2004. PMID: 15152391 Dutch.
-
Sentinel node identification by scintigraphic methods in cutaneous melanoma.J Exp Clin Cancer Res. 2005 Jun;24(2):181-5. J Exp Clin Cancer Res. 2005. PMID: 16110749
-
Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node.J Exp Clin Cancer Res. 2007 Mar;26(1):109-15. J Exp Clin Cancer Res. 2007. PMID: 17550139
-
Sentinel lymph node biopsy and melanoma biology.Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2320s-2325s. doi: 10.1158/1078-0432.CCR-05-2506. Clin Cancer Res. 2006. PMID: 16609052 Review.
-
Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours.Pathology. 2004 Oct;36(5):478-84. doi: 10.1080/00313020412331282726. Pathology. 2004. PMID: 15370119 Review.
Cited by
-
Malignant melanoma and its stromal nonimmune microecosystem.J Oncol. 2012;2012:584219. doi: 10.1155/2012/584219. Epub 2012 Jun 28. J Oncol. 2012. PMID: 22811710 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous